CBUS
Cibus, Inc.1.5600
+0.0400+2.63%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
84.87MP/E (TTM)
-Basic EPS (TTM)
-2.71Dividend Yield
0%Recent Filings
8-K
8-K
Cibus appoints experienced director
Cibus, Inc. appointed Kimberly A. Box, a seasoned tech and healthcare executive with 29 years at Hewlett Packard and current board roles at McGrath RentCorp, to its board on September 11, 2025. She joins the Compensation and Nominating committees, plus a special committee eyeing strategic alternatives for shareholder value. Box receives prorated 2025 compensation of $60,000 cash and $90,000 in equity. This bolsters governance amid strategic reviews.
8-K
Cibus Q2 loss narrows, traits progress
Cibus, Inc. reported Q2 2025 net loss of $26.6 million, down from $28.5 million year-over-year, driven by cost reductions slashing R&D and SG&A expenses while cash hit $36.5 million after a $27.5 million public offering. Rice herbicide tolerance traits HT1 and HT3 advance toward 2027 Latin America launch and 2028 U.S. entry, with a new Semillano collaboration and HT3 delivery to a U.S. customer boosting momentum. Sustainable ingredients program eyes nominal 2025 revenues and 2026 expansion. Cash burn drops to $30 million annually by 2026, yet funding needs loom.
10-Q
Q2 FY2025 results
Cibus posted Q2 revenue of $0.9M, up 11% y/y from collaboration work on Rice and sustainable ingredients, while YTD revenue climbed 42% to $2.0M. Operating loss narrowed to $17.9M from $21.5M y/y, thanks to cost cuts trimming R&D 6% and SG&A 29%, though YTD swung wider to $59.5M after a $21.0M goodwill impairment. Net loss attributable to stockholders eased to $25.4M from $24.9M y/y, with diluted EPS improving 46% to $(0.61) on 41.6M shares—reconciles cleanly, no anti-dilution flags. Cash swelled to $36.5M after $47.8M in offerings, funding $25.4M operating burn; free cash flow not disclosed in the 10-Q. Streamlining to Rice weed traits preserves runway into Q2 2026. Yet regulatory hurdles in the EU could slow trait adoption.
8-K
Cibus cuts 34 jobs
Cibus, Inc. approved a workforce reduction of about 34 full-time employees on July 21, 2025, to sharpen its focus on near-term, funded commercial projects. This cut, set to wrap by year-end, will trigger $0.5 million in one-time severance and vacation charges in Q3. Streamlining saves cash, yet biotech risks loom large.
AGTX
Agentix Corp.
0.04+0.00
AIBT
Aibotics Inc.
0.00+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
EXOZ
eXoZymes Inc.
12.52-1.78
FBLG
FibroBiologics, Inc.
0.24-0.02
IBIO
iBio, Inc.
2.06+0.23
IMA
ImageneBio, Inc.
6.25+0.08
NRXS
Neuraxis, Inc.
2.70+0.05
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07